Transcutol in topical formulation

Why co-solvency, degree of saturation, and the endpoint being measured matter more than a one-word “enhancer” label.

Start with the solvent job

Transcutol® P is the manufacturer's name for high-purity diethylene glycol monoethyl ether (DEGEE). In a multi-solvent liquid, a co-solvent is used alongside other solvents to change how much of a compound the vehicle can dissolve. That can make a target concentration physically possible and help formulation development begin with a single liquid phase.

It does not, by itself, show that the finished product will remain homogeneous over time or predict what will enter, remain in, or cross skin. Those are separate questions that must be measured on the complete formulation.

Solubility is not thermodynamic activity

A bottle concentration tells us how much material is present. It does not tell us how strongly that material tends to leave the vehicle. A useful formulation measure is degree of saturation: the dissolved concentration relative to the equilibrium solubility in that same vehicle under the same conditions. It is one practical indicator of thermodynamic driving force.

A stronger solvent can raise solubility substantially. At an unchanged loading, that can leave the compound farther below saturation, even though the liquid can hold more of it. “More soluble” therefore does not automatically mean “more permeation.” In an in-vitro human-skin experiment, Bialik and colleagues found that increasing the water fraction of water/Transcutol mixtures increased ibuprofen permeation; they attributed the result probably to changing thermodynamic activity. That finding belongs to ibuprofen and that experimental system—not to RU58841.

The donor also changes after it is placed on a surface. In a finite-dose study spanning saturated methylparaben solutions in ethanol and ethanol mixed with several non-volatile vehicles, including Transcutol P, Oliveira and colleagues measured rapid ethanol loss. In the saturated ethanol-only condition, depletion caused most of the applied methylparaben to crystallise. The broader lesson is modest but important: evaporation can change vehicle composition, saturation, and the amount still available to move.

Three endpoints, three different questions

Skin penetration: Entry into and distribution among defined skin layers under a stated method and exposure time.
Skin retention or deposition: The amount recovered from one or more skin layers after the surface has been cleaned and the tissue analysed.
Permeation: Passage across the tested membrane into a receptor compartment in an in-vitro or ex-vivo diffusion experiment.

These outcomes can move in different directions. In a hairless mouse-skin experiment, Godwin and colleagues varied Transcutol CG from 0% to 50% while holding two ultraviolet absorbers at 6%. Skin accumulation increased with Transcutol concentration, while transdermal permeation did not differ significantly for either absorber. That is a useful demonstration of distinct endpoints, not a transferable prediction for another compound.

Mechanism can differ too. Harrison and colleagues reported roughly twofold higher flux of the model permeant 4-cyanophenol across human stratum corneum in vitro. Their measurements suggested that Transcutol increased the permeant's solubility within the barrier, rather than primarily reducing its diffusional resistance. Again, the active, vehicle, tissue, dose, and method define the result.

Why there is no universal “mild” or “strong” rating

A vehicle component cannot be assigned a portable enhancement score. Compound properties and loading, solvent ratios, water activity, volatility, dose, occlusion, exposure time, skin source, membrane preparation, and the analytical endpoint can all change the observation. Results from a gel, vesicle, saturated solution, animal membrane, or different active are not interchangeable.

None of the Transcutol experiments cited here studied RU58841. They explain why formulation-specific evidence is needed; they do not establish how a particular RU58841 vehicle performs.

What the 2026 RU58841 human study does—and does not—show

Okutan and colleagues studied one topical scalp application in six healthy male volunteers. The internet-purchased product was labelled 50 mg/mL, but the researchers measured 30 mg/mL. One millilitre was applied, so the administered dose was 30 mg. The reported vehicle contained alcohol, water, and propylene glycol; it did not contain Transcutol.

After that single application, the parent compound and an oxidised metabolite were detected in dried blood spots, and five metabolites were detected in urine. This is direct evidence of systemic availability under those specific conditions. It does not quantify the total absorbed fraction, establish a chronic exposure pattern, or determine clinical efficacy or safety. The unchanged urinary steroid-profile markers in this single-dose experiment are not an endocrine safety assessment.

Because the study had no vehicle comparison and used no Transcutol, it cannot show that DEGEE would increase or decrease RU58841 exposure. It also studied a finished liquid—not raw RU58841 powder.

How to read our vehicle disclosures

The catalogue discloses the nominal vehicle systems below. A ratio identifies composition; it is not a performance, efficacy, or safety claim.

EtOH / PG — 70 / 30: A two-component ethanol and propylene glycol vehicle.
EtOH / PG / Transcutol — 70 / 20 / 10: A three-component vehicle containing 10 parts DEGEE.
EtOH / PG / Transcutol — 55 / 25 / 20: A three-component vehicle containing 20 parts DEGEE.

A raw-material report can document the identity and measured purity of the sample tested. It cannot establish the behaviour of a later finished liquid. Finished-product questions require evidence on that exact product—for example assay and physical stability, precipitation after solvent loss, and validated retention and permeation testing. A question about human systemic exposure would require an appropriately designed human study.

Primary sources and technical identity

The experimental papers below are linked to the original report. The Gattefossé link is the manufacturer's technical identification of Transcutol P, not independent performance evidence.